by Admin | August 21, 2015 10:07 am
[1]August 21, 2015—The Health Resources and Services Administration should clarify in a forthcoming 340B program rule that drugmakers must give refunds for all overcharges on 340B drugs above a reasonable dollar amount and within a reasonable amount of time after their discovery, including those due to routine average manufacturer price “true-ups,” groups representing healthcare providers urged in a public filing this week. They said HRSA also should clarify that providers are not required to request such refunds or credits.
Source URL: https://340binformed.org/2015/08/healthcare-providers-comment-on-340b-program-proposed-rule/
Copyright ©2024 340binformed.org unless otherwise noted.